GlassScriptPhysician profile
Alvin Abaqueta
NPI 1235102187
$10,629.96
in general payments reported to CMS, 2019-2025
63 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,686 · 2020: $946 · 2021: $1,842 · 2022: $1,356 · 2023: $1,583 · 2024: $1,807 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,750 · Long Term Medical Supply Or Device Loan: $49.95 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,750.32 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $922.50 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $893.20 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $755.15 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $639.25 | 2019-2025 | |
| Bausch Health US, LLC | $603.01 | 2020-2025 | Wellbutrin, Aplenzin |
| Bayer Healthcare Pharmaceuticals INC. | $500.20 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $429.95 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $416.67 | 2019-2022 | |
| Amarin Pharma, INC. | $368.22 | 2019-2022 | |
| Merz North America, INC. | $367.21 | 2019 | |
| Eisai INC. | $346.32 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.13 | 2021-2025 | Jardiance |
| Amgen INC. | $305.52 | 2019-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $293.48 | 2020-2025 | Nexletol |
| Avanir Pharmaceuticals, INC. | $272.73 | 2019-2022 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $237.61 | 2019-2020 | |
| Pfizer INC. | $198.49 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.29 | 2019-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $160.51 | 2024-2025 | Freestyle Libre 3, Freestyle Insulinx, Eterna |
| Astellas Pharma US INC | $159.18 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $137.79 | 2020-2025 | Rexulti, Nuedexta |
| Collegium Pharmaceutical, INC. | $131.40 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $106.50 | 2021 | |
| Sanofi-Aventis U.S. LLC | $104.87 | 2019-2022 | |
| Abbvie INC. | $99.75 | 2022-2025 | Botox, Linzess, Viberzi |
| Azurity Pharmaceuticals, INC. | $98.97 | 2023-2025 | Horizant, Edarbi, Azmiro |
| Exact Sciences Corporation | $97.90 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $97.74 | 2023 | Quviviq |
| Forte Bio-Pharma LLC | $86.05 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Glaxosmithkline, LLC. | $82.16 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Convatec INC. | $77.39 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $77.04 | 2022-2023 | Ingrezza |
| Alkermes, INC. | $76.24 | 2023-2024 | Aristada, Lybalvi |
| Argenx US, INC. | $71.71 | 2025 | Vyvgart Hytrulo |
| Jazz Pharmaceuticals INC. | $60.06 | 2021 | |
| Nestle Healthcare Nutrition INC. | $59.04 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.69 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $56.08 | 2022-2025 | Capvaxive, Gardasil 9 |
| Cmp Pharma, INC. | $55.43 | 2020-2021 | |
| Ardelyx, INC. | $48.69 | 2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.74 | 2025 | Rexulti |
| Urovant Sciences INC | $45.02 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $40.25 | 2021-2023 | Austedo Xr |
| Viatris Specialty LLC | $35.26 | 2025 | Yupelri |
| Daiichi Sankyo INC. | $34.52 | 2023 | Injectafer |
| Acadia Pharmaceuticals INC | $32.57 | 2019-2024 | Nuplazid |
| Allergan, INC. | $29.11 | 2020-2022 | |
| Zimmer Biomet Holdings, INC. | $28.74 | 2025 | Persona |
| Phathom Pharmaceuticals, INC. | $27.48 | 2024 | Voquezna |
| Intuity Medical INC | $25.56 | 2022 | |
| Vivus LLC | $23.74 | 2020 | |
| Sumitomo Pharma America, INC. | $23.68 | 2023-2024 | Gemtesa |
| Biogen, INC. | $22.14 | 2021 | |
| Tms Neurohealth Centers INC. | $21.65 | 2025 | Tms Neurohealth Centers INC. |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.34 | 2022 | |
| Medtronic, INC. | $19.27 | 2021 | |
| Inspire Medical Systems, INC. | $17.87 | 2025 | Inspire |
| Gilead Sciences, INC. | $17.45 | 2019 | |
| Indivior INC. | $15.54 | 2024 | Perseris |
| Kyowa Kirin, INC. | $15.06 | 2023 | |
| Sun Pharmaceutical Industries INC. | $14.41 | 2019 | |
| Circassia INC. | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvin Abaqueta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.